Public
Recursion Pharmaceuticals
Nasdaq: RXRXRecursion describes itself as a clinical-stage 'TechBio' company that combines automated biology and machine learning to find drug candidates. Its most advanced…
Most advanced: Phase 2Verified Sep 2026
Neurology & brain health
Public
Hyperfine
Nasdaq: HYPRHyperfine makes the Swoop system, a portable, ultra-low-field MRI scanner for brain imaging at the point of care. The company was founded…
Most advanced: Approved/marketed productsVerified Sep 2026
Private startup
insitro
Not publicly tradedinsitro, founded by Daphne Koller, combines machine learning with human cellular data to identify disease drivers and design drug candidates. It has…
Most advanced: PreclinicalVerified Sep 2026
Private startup
Retro Biosciences
Not publicly tradedRetro Biosciences aims to extend healthy human lifespan through programs in autophagy, cell replacement and tissue reprogramming. Its lead oral drug, RTR242,…
Most advanced: Phase 1Verified Sep 2026
DeepTech + MedTechMixed / overview
Organoids and Lab-Grown Models: Could They Improve How We Test Treatments?
Organoids and organ-on-a-chip systems let researchers test drugs on human tissue models before people. The early evidence is promising but specific, and the models still miss much of real human biology.
Explainer6 min read